CN Bio’s PhysioMimix™ Multi-Organ Microphysiological System selected by The Scientist as a ‘Top 10 Innovation 2021’
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), has been recognised by The Scientist for developing a Top 10 Innovation of 2021. This year’s list includes CN Bio’s PhysioMimix™ Multi-Organ MPS; a next-generation OOC platform that provides advanced insights into the potential effects of novel therapeutics that…
CN Bio and iiCON announce COVID-19 research collaboration
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced a research collaboration with the Infection Innovation Consortium (iiCON), a global collaborative infectious disease R&D programme, to validate the next generation of COVID-19 research tools.
CN Bio expands service offering to support oncology drug discovery
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced the commercial launch of its Oncology Service in response to the global need to improve cancer drug discovery approval rates.
CN Bio licenses human gut microbiome modelling tool from MIT and Northeastern University
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), announced it has secured the licensing rights to a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of Technology (MIT) and Northeastern University.
Lonza and CN Bio announce distribution agreement
Basel, Switzerland and Cambridge, UK...– Lonza and CN Bio have entered into a distribution agreement whereby Lonza will supply a selection of hepatic cells to be prequalified by CN Bio for use in their PhysioMimixTM Single-and Multi-Organ MPS to transform the way human-relevant pre-clinical data is generated.
CN Bio’s PhysioMimix™ adopted by King’s College London to investigate chronic liver disease
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single and multi-organ microphysiological systems (MPS), today announced that King’s College London, an internationally renowned research university, has adopted the PhysioMimix™ Multi-Organ MPS.
FDA expands collaboration with CN Bio to investigate lung-on-a-chip model for inhaled drug evaluation applications
CN Bio, a leading developer of single- and multi-organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the US Food and Drug Administration (FDA) has extended their research collaboration for a further three years.
CN Bio introduces the PhysioMimix™ OOC Multi-Organ Microphysiological System
CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), has announced the commercial launch of its new PhysioMimix™ OOC Multi-Organ MPS.
CN Bio awarded Innovate UK grant to develop single and multi-organ models for COVID-19 research
CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip, today announced it has received a grant from Innovate UK, the UK’s innovation agency, to develop human-relevant MPS to advance investigations into SARS-CoV-2 infection.
CN Bio’s PhysioMimix technology receives FDA recognition
CN Bio, a leading developer of single and multi organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the publication of co-authored research with the US Food and Drug Administration (FDA)1.
CN Bio and University of Melbourne collaborate to advance therapies for respiratory complications in recovered COVID-19 patients
CN Bio, a leading cell culture company that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, today announced a collaboration with the University of Melbourne, focused on respiratory therapies for recovering COVID-19 patients.